1
|
Calvo I, Montilla A, Huergo C, Martín-Saiz L, Martín-Allende J, Tepavcevic V, Domercq M, Fernández JA. Combining imaging mass spectrometry and immunohistochemistry to analyse the lipidome of spinal cord inflammation. Anal Bioanal Chem 2024; 416:1923-1933. [PMID: 38326664 PMCID: PMC10902057 DOI: 10.1007/s00216-024-05190-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 01/10/2024] [Accepted: 01/29/2024] [Indexed: 02/09/2024]
Abstract
Inflammation is a complex process that accompanies many pathologies. Actually, dysregulation of the inflammatory process is behind many autoimmune diseases. Thus, treatment of such pathologies may benefit from in-depth knowledge of the metabolic changes associated with inflammation. Here, we developed a strategy to characterize the lipid fingerprint of inflammation in a mouse model of spinal cord injury. Using lipid imaging mass spectrometry (LIMS), we scanned spinal cord sections from nine animals injected with lysophosphatidylcholine, a chemical model of demyelination. The lesions were demonstrated to be highly heterogeneous, and therefore, comparison with immunofluorescence experiments carried out in the same section scanned by LIMS was required to accurately identify the morphology of the lesion. Following this protocol, three main areas were defined: the lesion core, the peri-lesion, which is the front of the lesion and is rich in infiltrating cells, and the uninvolved tissue. Segmentation of the LIMS experiments allowed us to isolate the lipid fingerprint of each area in a precise way, as demonstrated by the analysis using classification models. A clear difference in lipid signature was observed between the lesion front and the epicentre, where the damage was maximized. This study is a first step to unravel the changes in the lipidome associated with inflammation in the context of diverse pathologies, such as multiple sclerosis.
Collapse
Affiliation(s)
- Ibai Calvo
- Department of Physical Chemistry, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Bº Sarriena s/n, 48940, Leioa, Spain
| | - Alejandro Montilla
- Achucarro Basque Center for Neurosciencie, Bº Sarriena s/n, 48940, Leioa, Spain
- Department Neuroscience, Faculty of Medicine, University of the Basque Country (UPV/EHU), Bº Sarriena s/n, 48940, Leioa, Spain
| | - Cristina Huergo
- Department of Physical Chemistry, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Bº Sarriena s/n, 48940, Leioa, Spain
| | - Lucía Martín-Saiz
- Department of Physical Chemistry, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Bº Sarriena s/n, 48940, Leioa, Spain
| | - Javier Martín-Allende
- Department of Languages and Computer Systems, School of Engineering, University of the Basque Country (UPV/EHU), Paseo Rafael Moreno "Pitxitxi", n. 2/3, 48013, Bilbao, Spain
| | - Vanja Tepavcevic
- Achucarro Basque Center for Neurosciencie, Bº Sarriena s/n, 48940, Leioa, Spain
| | - María Domercq
- Achucarro Basque Center for Neurosciencie, Bº Sarriena s/n, 48940, Leioa, Spain.
- Department Neuroscience, Faculty of Medicine, University of the Basque Country (UPV/EHU), Bº Sarriena s/n, 48940, Leioa, Spain.
| | - José A Fernández
- Department of Physical Chemistry, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Bº Sarriena s/n, 48940, Leioa, Spain.
| |
Collapse
|
2
|
Machado ER, van de Vlekkert D, Sheppard HS, Perry S, Downing SM, Laxton J, Ashmun R, Finkelstein DB, Neale GA, Hu H, Harwood FC, Koo SC, Grosveld GC, d'Azzo A. Haploinsufficiency of the lysosomal sialidase NEU1 results in a model of pleomorphic rhabdomyosarcoma in mice. Commun Biol 2022; 5:992. [PMID: 36127469 PMCID: PMC9489700 DOI: 10.1038/s42003-022-03968-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Accepted: 09/08/2022] [Indexed: 11/08/2022] Open
Abstract
Rhabdomyosarcoma, the most common pediatric sarcoma, has no effective treatment for the pleomorphic subtype. Still, what triggers transformation into this aggressive phenotype remains poorly understood. Here we used Ptch1+/-/ETV7TG/+/- mice with enhanced incidence of rhabdomyosarcoma to generate a model of pleomorphic rhabdomyosarcoma driven by haploinsufficiency of the lysosomal sialidase neuraminidase 1. These tumors share mostly features of embryonal and some of alveolar rhabdomyosarcoma. Mechanistically, we show that the transforming pathway is increased lysosomal exocytosis downstream of reduced neuraminidase 1, exemplified by the redistribution of the lysosomal associated membrane protein 1 at the plasma membrane of tumor and stromal cells. Here we exploit this unique feature for single cell analysis and define heterogeneous populations of exocytic, only partially differentiated cells that force tumors to pleomorphism and promote a fibrotic microenvironment. These data together with the identification of an adipogenic signature shared by human rhabdomyosarcoma, and likely fueling the tumor's metabolism, make this model of pleomorphic rhabdomyosarcoma ideal for diagnostic and therapeutic studies.
Collapse
Affiliation(s)
- Eda R Machado
- Department of Genetics, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | | | - Heather S Sheppard
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Scott Perry
- Flow Cytometry Core Facility, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Susanna M Downing
- Department of Cell & Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Jonathan Laxton
- Flow Cytometry Core Facility, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Richard Ashmun
- Flow Cytometry Core Facility, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - David B Finkelstein
- Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Geoffrey A Neale
- Hartwell Center for Bioinformatics and Biotechnology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Huimin Hu
- Department of Genetics, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Frank C Harwood
- Department of Genetics, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Selene C Koo
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Gerard C Grosveld
- Department of Genetics, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
| | - Alessandra d'Azzo
- Department of Genetics, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
| |
Collapse
|
3
|
Sela Y, Li J, Maheswaran S, Norgard R, Yuan S, Hubbi M, Doepner M, Xu JP, Ho E, Measaros C, Sheehan C, Croley G, Muir A, Blair IA, Shalem O, Dang CV, Stanger BZ. Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer. Cancer Res 2022; 82:1890-1908. [PMID: 35315913 PMCID: PMC9117449 DOI: 10.1158/0008-5472.can-22-0431] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Revised: 03/13/2022] [Accepted: 03/15/2022] [Indexed: 12/24/2022]
Abstract
Solid tumors possess heterogeneous metabolic microenvironments where oxygen and nutrient availability are plentiful (fertile regions) or scarce (arid regions). While cancer cells residing in fertile regions proliferate rapidly, most cancer cells in vivo reside in arid regions and exhibit a slow-cycling state that renders them chemoresistant. Here, we developed an in vitro system enabling systematic comparison between these populations via transcriptome analysis, metabolomic profiling, and whole-genome CRISPR screening. Metabolic deprivation led to pronounced transcriptional and metabolic reprogramming, resulting in decreased anabolic activities and distinct vulnerabilities. Reductions in anabolic, energy-consuming activities, particularly cell proliferation, were not simply byproducts of the metabolic challenge, but rather essential adaptations. Mechanistically, Bcl-xL played a central role in the adaptation to nutrient and oxygen deprivation. In this setting, Bcl-xL protected quiescent cells from the lethal effects of cell-cycle entry in the absence of adequate nutrients. Moreover, inhibition of Bcl-xL combined with traditional chemotherapy had a synergistic antitumor effect that targeted cycling cells. Bcl-xL expression was strongly associated with poor patient survival despite being confined to the slow-cycling fraction of human pancreatic cancer cells. These findings provide a rationale for combining traditional cancer therapies that target rapidly cycling cells with those that target quiescent, chemoresistant cells associated with nutrient and oxygen deprivation. SIGNIFICANCE The majority of pancreatic cancer cells inhabit nutrient- and oxygen-poor tumor regions and require Bcl-xL for their survival, providing a compelling antitumor metabolic strategy.
Collapse
Affiliation(s)
- Yogev Sela
- Departments of Medicine and Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
- Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
| | - Jinyang Li
- Departments of Medicine and Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
- Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
| | - Shivahamy Maheswaran
- Departments of Medicine and Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
- Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
| | - Robert Norgard
- Departments of Medicine and Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
- Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
| | - Salina Yuan
- Departments of Medicine and Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
- Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
| | - Maimon Hubbi
- Departments of Medicine and Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
- Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
| | - Miriam Doepner
- Departments of Medicine and Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
| | - Jimmy P. Xu
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
| | - Elaine Ho
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
| | - Clementina Measaros
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
| | - Colin Sheehan
- Ben May Department of Cancer Research, University of Chicago, Chicago, IL 60637, USA
| | - Grace Croley
- Ben May Department of Cancer Research, University of Chicago, Chicago, IL 60637, USA
| | - Alexander Muir
- Ben May Department of Cancer Research, University of Chicago, Chicago, IL 60637, USA
| | - Ian A. Blair
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
| | - Ophir Shalem
- Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
- Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | - Chi V. Dang
- Systems and Computational Biology Center and Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, 19104, USA
- Ludwig Institute for Cancer Research, New York, 10016, USA
| | - Ben Z. Stanger
- Departments of Medicine and Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
- Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA
| |
Collapse
|
4
|
Smith H, De Souza D, Tull D, McConville M, Pellagatti A, Boultwood J, Board M, Callaghan R. The utilisation of glutamine and glucose by a 3-D tumour model trapped in quiescence. Int J Biochem Cell Biol 2021; 133:105935. [PMID: 33529714 DOI: 10.1016/j.biocel.2021.105935] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2020] [Revised: 01/06/2021] [Accepted: 01/08/2021] [Indexed: 11/29/2022]
Abstract
Solid tumours modify their metabolic strategy to ensure sufficient biomass and energy to maintain a high rate of proliferation. However, solid tumours are characterised by a high proportion of quiescent cells and little is known about their metabolic profile. A tumour spheroid model with DLD1 cells was used to investigate the influence of a quiescent state on the cellular utilisation of glucose and glutamine. Quiescent DLD1 spheroids displayed increased depletion of both nutrients from the bathing medium compared to their proliferative counterparts and displayed highly active overall metabolism. A combination of biochemical and metabolomics approaches demonstrated that glucose utilisation resulted in an increased production of the 3-carbon intermediates lactate and alanine in quiescent spheroids. In addition, glutamine metabolism was directed to anabolic pathways; including the "reverse TCA cycle" to produce citrate for fatty-acid synthesis. These adaptations in DLD1 spheroids may propose a metabolic altruism of quiescent regions in solid tumours to provide biosynthetic intermediates required to sustain tumour growth, angiogenesis and metastasis.
Collapse
Affiliation(s)
- Hannah Smith
- Nuffield Department of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - David De Souza
- Metabolomics Australia, Bio21 Institute, University of Melbourne, Melbourne, Australia
| | - Dedreia Tull
- Metabolomics Australia, Bio21 Institute, University of Melbourne, Melbourne, Australia
| | - Malcolm McConville
- Metabolomics Australia, Bio21 Institute, University of Melbourne, Melbourne, Australia
| | - Andrea Pellagatti
- Nuffield Department of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre Haematology Theme, Oxford, UK
| | - Jacqueline Boultwood
- Nuffield Department of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre Haematology Theme, Oxford, UK
| | - Mary Board
- Nuffield Department of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - Richard Callaghan
- Nuffield Department of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Research School of Biology, and the Medical School, Australian National University Canberra, ACT 2601, Australia.
| |
Collapse
|
5
|
Mody K, Mansfield AS, Vemireddy L, Nygren P, Gulbo J, Borad M. A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors. Invest New Drugs 2019; 37:684-92. [DOI: 10.1007/s10637-018-0703-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Accepted: 11/15/2018] [Indexed: 12/16/2022]
|
6
|
Affiliation(s)
- Lucian R Chirieac
- Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
| |
Collapse
|
7
|
Abstract
One characteristic of solid tumors such as malignant melanoma is the acidification of the tumor microenvironment. The deregulation of cancer cell metabolism is considered a main cause of extracellular acidosis. Here, cancer cells utilize aerobic glycolysis instead of oxidative phosphorylation even under normoxic conditions, as originally described by Otto Warburg. These metabolic alterations cause enhanced acid production, especially of lactate and carbon dioxide (CO2 ). The extensive production of acidic metabolites and the enhanced acid export to the extracellular space cause a consistent acidification of the tumor microenvironment, thus promoting the formation of an acid-resistant tumor cell population with increased invasive and metastatic potential. As melanoma is one of the deadliest and most metastatic forms of cancer, understanding the effects of this extracellular acidosis on human melanoma cells with distinct metastatic properties is important. The aim of this review was to summarize recent studies of the acidification of the tumor microenvironment, focusing on the specific effects of the acidic milieu on melanoma cells and to give a short overview of therapeutic approaches.
Collapse
Affiliation(s)
- Ines Böhme
- Institute of Biochemistry, Emil-Fischer-Centrum, Friedrich Alexander University Erlangen-Nürnberg, Erlangen-Nürnberg, Germany
| | - Anja Katrin Bosserhoff
- Institute of Biochemistry, Emil-Fischer-Centrum, Friedrich Alexander University Erlangen-Nürnberg, Erlangen-Nürnberg, Germany. .,Comprehensive Cancer Center Erlangen-EMN, University of Erlangen, Erlangen, Germany.
| |
Collapse
|
8
|
Zhang X, Fryknäs M, Hernlund E, Fayad W, De Milito A, Olofsson MH, Gogvadze V, Dang L, Påhlman S, Schughart LAK, Rickardson L, D'Arcy P, Gullbo J, Nygren P, Larsson R, Linder S. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat Commun 2015; 5:3295. [PMID: 24548894 PMCID: PMC3929804 DOI: 10.1038/ncomms4295] [Citation(s) in RCA: 171] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2013] [Accepted: 01/21/2014] [Indexed: 12/19/2022] Open
Abstract
Abnormal vascularization of solid tumours results in the development of microenvironments deprived of oxygen and nutrients that harbour slowly growing and metabolically stressed cells. Such cells display enhanced resistance to standard chemotherapeutic agents and repopulate tumours after therapy. Here we identify the small molecule VLX600 as a drug that is preferentially active against quiescent cells in colon cancer 3-D microtissues. The anticancer activity is associated with reduced mitochondrial respiration, leading to bioenergetic catastrophe and tumour cell death. VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation. Importantly, VLX600 displays tumour growth inhibition in vivo. Our findings suggest that tumour cells in metabolically compromised microenvironments have a limited ability to respond to decreased mitochondrial function, and suggest a strategy for targeting the quiescent populations of tumour cells for improved cancer treatment. Quiescent sub-populations of cells in tumours are resistant to traditional chemotherapeutics and are responsible for tumour recurrence. Here, Zhang et al. identify a compound that kills quiescent tumour cells in solid tumour tissue by inducing mitochondrial dysfunction.
Collapse
Affiliation(s)
- Xiaonan Zhang
- 1] Department of Oncology-Pathology, Karolinska Institute, Stockholm S-171 76, Sweden [2]
| | - Mårten Fryknäs
- 1] Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala S-751 85, Sweden [2]
| | - Emma Hernlund
- Department of Oncology-Pathology, Karolinska Institute, Stockholm S-171 76, Sweden
| | - Walid Fayad
- 1] Department of Oncology-Pathology, Karolinska Institute, Stockholm S-171 76, Sweden [2]
| | - Angelo De Milito
- Department of Oncology-Pathology, Karolinska Institute, Stockholm S-171 76, Sweden
| | - Maria Hägg Olofsson
- Department of Oncology-Pathology, Karolinska Institute, Stockholm S-171 76, Sweden
| | - Vladimir Gogvadze
- Division of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm 171 77, Sweden
| | - Long Dang
- Division of Hematology/Oncology, Department of Internal Medicine, University of Florida Shands Cancer Center, University of Florida, Gainesville, Florida 32601, USA
| | - Sven Påhlman
- Department of Laboratory Medicine, Center for Molecular Pathology, CREATE Health, Skåne University Hospital, Lund University, S-20502, Malmö, Sweden
| | - Leoni A Kunz Schughart
- OncoRay-National Center for Radiation Research in Oncology, TU Dresden, Dresden 01307, Germany
| | - Linda Rickardson
- Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala S-751 85, Sweden
| | - Padraig D'Arcy
- Department of Oncology-Pathology, Karolinska Institute, Stockholm S-171 76, Sweden
| | - Joachim Gullbo
- 1] Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala S-751 85, Sweden [2] Division of Oncology, Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala S-751 85, Sweden
| | - Peter Nygren
- Division of Oncology, Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala S-751 85, Sweden
| | - Rolf Larsson
- Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala S-751 85, Sweden
| | - Stig Linder
- 1] Department of Oncology-Pathology, Karolinska Institute, Stockholm S-171 76, Sweden [2] Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala S-751 85, Sweden
| |
Collapse
|
9
|
Abstract
BACKGROUND Breast cancer is not a homogeneous disease, but several different and unique subtypes defined by gene expression analysis. Incidence and mortality rates vary by almost 3-fold between Alaska (highest) and the Southwestern tribes (lowest). We hypothesized that these differences may be due to, in part, varying levels of biologic tumor aggressiveness. METHODS A biorepository of the North Central Cancer Treatment Group with 95 cases of American Indian and Alaska Native (AIAN) women with adenocarcinoma of the breast surgically treated from 1990 to 2000 was tested for several biomarkers. Comparison distributions of biomarker values across state of residence using t tests for continuous (p53, MIB-1, cyclin D) and ordinally scaled markers [EGF receptor (EGFR), BCL-2, Her2] and χ(2) tests of significance for binary markers [estrogen receptor (ER), progesterone receptor (PR)] were done. RESULTS Significant regional differences in some biomarker expression levels were seen. No increase was observed in "triple-negative" breast cancer or Her2 overexpression in these cases. CONCLUSIONS Despite a 3-fold difference in breast cancer mortality in Alaska Native versus Southwestern American Indians, standard biomarkers such as ER, PR, and Her2 neu expression did not explain the disparity. IMPACT There is a need for research to understand the biologic basis of breast cancer disparities in AIAN women. Potential for a prospective trial will be explored with tribes.
Collapse
Affiliation(s)
- Judith S Kaur
- Authors' Affiliations: Divisions of Medical Oncology and Anatomical Pathology; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota
| | | | | | | |
Collapse
|
10
|
Gallois M, Rothkötter HJ, Bailey M, Stokes CR, Oswald IP. Natural alternatives to in-feed antibiotics in pig production: can immunomodulators play a role? Animal 2009; 3:1644-61. [PMID: 22443549 DOI: 10.1017/S1751731109004236] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
As a result of the European ban of in-feed growth-promoting antibiotics, new strategies are being developed to increase the resistance to disease in farm animals. In pig production, this is of particular importance during the weaning transition when piglets are subjected to major stressful events, making them highly sensitive to digestive disorders. At this time, the development of both innate and adaptive immunity at the mucosal surface is critical in preventing the potential harmful effects of intestinal pathogenic agents. Strategies aiming at stimulating natural host defences through the use of substances able to modulate immune functions have gained increasing interest in animal research, and different bioactive components a priori sharing those properties have been the subject of in vivo nutritional investigations in pig. Among these, yeast derivates (β-glucans and mannans) are able to interact with immune cells, particularly phagocytic cells. However, studies where they have been fed to pigs have shown inconsistent results, suggesting that their ability to target the sensitive immune cells through the oral route is questionable. The plant extracts, which would benefit from a positive image in the public opinion, have also been tested. However, due to a lack of data on the bioactive components of particular plants and the large diversity of species, it has proved difficult to prepare extracts of equivalent potency and thus, the literature on their influence on pig immunity remains inconclusive. In considering piglet immunity and health benefits, the most promising results to date have been obtained with spray-dried animal plasma, whose positive effects would be provided by specific antibodies and non-specific competition of some plasma components with bacteria for intestinal receptors. The major positive effect of spray-dried animal plasma is in reducing the infiltration of gut-associated lymphoid tissue by immune cells, which is likely to be the result of a decreased colonisation by potentially harmful bacteria. This review also highlights the limitations of some of the published in vivo studies on the immunomodulatory activity of certain feed additives. Among those, the lack of standardisation of extracts and the heterogeneity of piglet-rearing conditions (e.g. exposure to pathogens) are likely the most limiting.
Collapse
|
11
|
Jong R, Davis AM, Mendes MG, Wunder JS, Bell RS, Kandel R. Proliferative activity (ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases. Sarcoma 2000; 4:47-55. [PMID: 18521434 DOI: 10.1155/S1357714X00000086] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Purpose. Although pre-operative chemotherapy has improved the
prognosis for individuals with osteosarcoma, approximately 40% of patients will die of their
disease.The aim of this study was to quantitate proliferative activity in high grade
osteosarcomas and to determine whether proliferation is a prognostic factor. Patients. The study consisted of 27 patients with high grade
non-metastatic osteosarcoma at various sites for whom pre-operative biopsies and
resection specimens were available for review. All patients were treated similarly and
had at least 24 months' follow-up from the date of diagnosis. Methods. Proliferative activity (Ki-67 expression) was examined in the
diagnostic biopsies immunohistochemically using the MIB-1 antibody. Proliferation was
quantitated in two ways; (1) the number of immunopositive cells was counted manually
using an ocular grid; or (2) the percentage of immunopositive nuclear area was assessed
using morphometric image analysis. Proliferative index was evaluated in relation to
patient outcome. Results. Proliferative activity was seen in all biopsies.The median
proliferative index as determined by counting cells was 24% (mean of 27%, range of 7–61%)
and by image analysis was 2% (mean 3%, range 0.32–8.4).The correlation between
MIB-1 proliferation indices determined either by image analysis methodology or manual cell
counting was high (Spearman's rho=0.79). Proliferative index did not appear to predict either
disease-free or overall survival. Discussion. Tumor proliferation does not appear to be prognostic for
high grade osteosarcomas.Whether assessment of this feature in conjunction with other
tumor characteristics might be prognostic requires further study.
Collapse
|
12
|
Abstract
Aims-To investigate the tumour cell proliferative index obtained by immunostaining of paraffin wax sections of 30 cases of breast carcinoma with monoclonal antibodies MIB1, KiS1 and KiS5, and polyclonal Ki67 antisera to the Ki67 antigen and 19A2 and PC10 antibodies to proliferating cell nuclear antigen and the possible correlation between these indices and that of monoclonal Ki67 antibody in frozen sections of the same tumours.Methods-All tumour samples had been uniformly fixed and processed and sections were subjected to microwave antigen retrieval before immunostaining in all instances except for monoclonal Ki67 antibody which was used in cryostat sections. Tumour cell proliferative indices were evaluated by two independent examiners, each counting 500 tumour cells with the aid of a cross-hatched grid.Results-Proliferative indices obtained with MIB1, polyclonal Ki67, KiS1, and KiS5 correlated with those obtained with monoclonal Ki67 in frozen sections. Proliferative indices obtained with monoclonal 19A2 and PC10 showed no correlation with those of monoclonal Ki67 antibody. The staining obtained with MIB1 was the most intense and the easiest to read.Conclusions-Monoclonal antibodies MIB1, KiS1 and KiS5 and polyclonal Ki67 antiserum appear to be suitable substitutes for monoclonal antibody Ki67 in the assessment of tumour cell proliferative index. As these reagents are all immunoreactive in paraffin wax sections, they overcome the requirement for frozen tissue for immunostaining with monoclonal Ki67.
Collapse
Affiliation(s)
- A S Leong
- Division of Tissue Pathology, Institute of Medical & Veterinary Science, Frome Road, Adelaide, South Australia 5000
| | | | | | | |
Collapse
|
13
|
Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty PA, Coukos G. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009; 115:2891-902. [PMID: 19472394 DOI: 10.1002/cncr.24317] [Citation(s) in RCA: 106] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND The aim of the study was to determine whether tumor-infiltrating lymphocytes and/or tumor mitotic activity could identify subgroups of patients with advanced serous epithelial ovarian cancer who would maximally benefit from aggressive surgical cytoreduction. METHODS Snap-frozen specimens from 134 consecutive patients with stage III or IV serous or poorly differentiated ovarian adenocarcinoma undergoing primary debulking surgery from a single US institution were characterized based on CD3(+), CD8(+), FoxP3(+) tumor-infiltrating lymphocytes, and Ki67 expression. Kaplan-Meier survival curves were estimated and compared using a log-rank statistic. A multivariate Cox model was used to estimate adjusted hazard ratios. Interactions were modeled using recursive partitioning based on maximal prognostic differentiation. RESULTS Brisk intraepithelial CD8(+) cells (P = .035) and low Ki67 expression (P = .042) portended prolonged survival. The T-cell infiltration was more likely to occur in tumors with high proliferation index. Patients whose tumors exhibited low Ki67 expression and high intraepithelial CD8(+) frequency had a 5-year survival rate of 73.3%. Patients with aggressive tumor behavior, that is, whose tumors exhibited low frequency of intraepithelial CD8(+) T cells or high Ki67 expression were more likely to draw benefit from aggressive surgical cytoreduction. Survival was similar for patients with brisk CD8(+) T cells who had optimal or suboptimal debulking. Likewise, survival was similar for patients with low Ki67 expression who had optimal or suboptimal debulking. CONCLUSIONS For the first time, these novel interactions of T cells, tumor proliferation index, and surgical treatment reveal that biological prognosticators may be useful for surgical decision making in ovarian cancer.
Collapse
Affiliation(s)
- Sarah F Adams
- Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 2008; 81:275-300. [PMID: 18259091 DOI: 10.1159/000115967] [Citation(s) in RCA: 121] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2007] [Accepted: 09/10/2007] [Indexed: 12/30/2022]
Abstract
Inherent and acquired resistance pathways account for the high rate of failure in cancer chemotherapy. The mechanisms or pathways mediating resistance may be classified as pharmacokinetic (i.e. alter intratumour drug exposue) or pharmacodynamic (i.e. failure to elicit cytotoxicity). More often than not, the resistant phenotype is characterised by alterations in multiple pathways. Consequently, the pathways may act synergistically or generate a broad spectrum of resistance to anticancer drugs. There has been a great deal of systematic characterisation of drug resistance in vitro. However, translating this greater understanding into clinical efficacy has rarely been achieved. This review explores the phenomenon of drug resistance in cancer and highlights the gap between in vitro and in vivo observations. This gap presents a major obstacle in overcoming drug resistance and restoring sensitivity to chemotherapy.
Collapse
Affiliation(s)
- Howard R Mellor
- Growth Factor Group, Weatherall Institute of Molecular Medicine, Oxford, UK
| | | |
Collapse
|
15
|
Abstract
To assess the expression of the homeogene Pax-2 in adult renal cell carcinomas, we did a retrospective immunohistochemical analysis of 56 frozen tumor samples representing all major histologic subtypes of renal tumors. There were 33 conventional renal cell carcinomas (58.9%), 12 papillary renal cell carcinomas (21.4%), 4 chromophobe cell renal carcinomas, 4 urothelial cell renal carcinomas, and 3 oncocytomas. Forty-five tumors (62.5%) were localized, and 21 tumors had extrarenal involvement. Eight patients (14%) had metastatic disease at the end of the follow-up. We searched for relationships between Pax-2 expression and nuclear grading, TNM staging, Ki-67 proliferation index, expression of transforming growth factor-beta1 (TGF-beta 1), an in vitro down-regulator of Pax-2 expression, and finally cytogenetic abnormalities. All histologic subtypes expressed Pax-2 protein, except urothelial renal carcinomas. The highest expression was in papillary renal cell carcinomas. In this subtype, all tumors and 83.3% +/- 12.3% of tumor cells were immunoreactive for Pax-2. All but 2 conventional renal cell carcinomas expressed Pax-2, but with 26.3% +/- 29.6% of immunoreactive cells (P <.001). Pax-2 expression was not correlated with nuclear grading (P =.6), tumor size (P =.3), and TGF-beta 1 expression (P =.1). Nevertheless, Pax-2 expression correlated with the Ki-67 proliferation index only for the conventional histologic subtype (P =.03). In this histologic subtype, Pax-2 expression was higher in patients with metastatic disease than in those without (P =.02). Pax-2 expression was not associated with specific cytogenetic abnormalities like trisomy 7 (P =.1), 3p deletion (P =.5), and hyperdiploidy (P =.2). TGF-beta 1 expression, positive in 33 tumors (59%), was not correlated with either Pax-2 expression (P =.1) or current prognostic factors such as nuclear grading (P =.2). Interestingly, we also observed an expression of TGF-beta RI and TGF-beta RII in the tumors with high nuclear grading (P =.005). We conclude that Pax-2 protein is expressed in all major histologic subtypes of renal cell carcinomas. The pattern of expression differs between these subtypes. Pax-2 expression in conventional renal cell carcinomas is correlated with the proliferation index and is significantly higher in patients with metastatic disease. HUM PATHOL 32:282-287.
Collapse
MESH Headings
- Adenoma, Oxyphilic/chemistry
- Adenoma, Oxyphilic/genetics
- Adenoma, Oxyphilic/pathology
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Papillary/chemistry
- Carcinoma, Papillary/genetics
- Carcinoma, Papillary/pathology
- Carcinoma, Renal Cell/chemistry
- Carcinoma, Renal Cell/genetics
- Carcinoma, Renal Cell/pathology
- Cell Division
- Cell Nucleus/pathology
- Chromosome Aberrations
- Cryopreservation
- Cytogenetic Analysis
- DNA-Binding Proteins/analysis
- Female
- Humans
- Immunohistochemistry
- Ki-67 Antigen/analysis
- Kidney Neoplasms/chemistry
- Kidney Neoplasms/genetics
- Kidney Neoplasms/pathology
- Male
- Middle Aged
- Neoplasm Metastasis
- PAX2 Transcription Factor
- Retrospective Studies
- Transcription Factors/analysis
- Transforming Growth Factor beta/analysis
Collapse
Affiliation(s)
- L Daniel
- Department of Pathology, CHU Timone, Marseille, France
| | | | | | | | | | | | | |
Collapse
|
16
|
Coste A, Rateau JG, Bernaudin JF, Peynègre R, Escudier E. Nasal polyposis pathogenesis: a flow cytometric and immunohistochemical study of epithelial cell proliferation. Acta Otolaryngol 1996; 116:755-61. [PMID: 8908256 DOI: 10.3109/00016489609137920] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
In nasal polyps, constantly associated with chronic inflammation, frequent epithelial morphological changes (squamous metaplasia, secretory hyperplasia) suggest a dysregulation of epithelial cell proliferation. Cell proliferation in nasal respiratory epithelium was therefore evaluated in nasal polyposis. In 20 patients, we compared cell proliferation in mucosa from the inferior turbinate to these in nasal polyps using two methods: Flow cytometry analyzing first the ploidy and the percentage of S-phase cells (propidium iodide DNA labeling), secondly the percentage of Ki-67-labeled cells and the green fluorescent index (fluorescein-conjugated anti-human Ki-67 antigen labeling, and thirdly the percentage of Ki-67-labeled cells being in S-phase. Immunohistochemistry, quantifying the expression of Ki-67 antigen in the epithelium permitting to calculate a Ki-67 index. All cell-populations studied were diploid. Percentages of S-phase cells, Ki-67-labeled cells, Ki-67 labeled cells being in the S-phase and green fluorescence index was significantly higher in nasal polyps than in mucosa Ki-67 index were significantly higher in nasal polyps than in mucosa in the epithelium. Epithelial cell proliferation which is therefore increased in nasal polyp could play an important role in nasal polyposis pathogenesis and its relationships with inflammation can be suggested.
Collapse
Affiliation(s)
- A Coste
- Service d'ORL, Hôpitaux Henri Mondor et Intercommunal de Créteil, France
| | | | | | | | | |
Collapse
|
17
|
Abstract
The expression of the anti-proliferating cell nuclear antigen (PCNA) was examined in bladder specimens from 48 patients with superficial transitional carcinoma, with the use of the PC10 monoclonal antibody. In vesical tumours with good clinical behaviour, we found a median PCNA positivity of 7.1% with a range of 5-25%. In vesical tumours with high incidence of recurrence, the median was 36.6% with a range of 15-80%. In vesical tumours with a strong tendency to invasion, the median positivity for PCNA staining was 68% with a range of 40-92%. In conclusion, we believe that using PC10 immunostaining to determine a nuclear proliferative fraction is a quick and simple method of studying the prognosis of patients who have vesical tumours of low grade and low stage.
Collapse
Affiliation(s)
- E Blasco-Olaetxea
- Instituto Vasco Biotecnología, Fundación Gipuzkoa, San Sebastián, Spain
| | | | | |
Collapse
|
18
|
Abstract
BACKGROUND Fatty acid synthase (FAS) is a molecule found in tumor cells from breast carcinomas of patients whose prognosis is very poor. Recently, this molecule has been identified as the key enzyme in fatty acid biosynthesis. This study was done to test the strength of FAS as a prognostic indicator for disease free survival (DFS) and overall survival (OS). METHODS Clinical records, histologic features, immunohistochemical expression of cathepsin D and c-erbB-2, and estrogen and progesterone receptor status of 110 Stage I breast carcinoma patients were all associated with FAS by a chi-square test. The patterns of DFS and OS were estimated over a ten-year follow-up period using the Kaplan-Meier method. Univariate and multivariate analysis were evaluated using a log logistic regression model. Multivariate regression analysis was based on the Cox proportional hazard model. To detect FAS, cathepsin D and c-erbB-2 expression as well as estrogen and progesterone receptor status, we used the unlabeled immunoperoxidase technique on formalin fixed, paraffin embedded tissue. RESULTS FAS was significantly associated with a higher risk of recurrence because it predicted both DFS (P = 0.0001) and OS (P = 0.003) when evaluated as a continuous variable and DFS (P = 0.0001) when evaluated with other prognostic markers. Peritumoral lymphatic vessel invasion was the other most significant independent predictor for DFS (P = 0.001) and OS (P = 0.003). CONCLUSIONS FAS is a reliable prognostic marker to predict DFS and OS in patients with early breast cancer.
Collapse
Affiliation(s)
- P L Alo'
- Dipartimento di Medicina Sperimentale e Patologia, Università di Roma La Sapienza, Italy
| | | | | | | | | | | |
Collapse
|
19
|
Choong PF, Akerman M, Willén H, Andersson C, Gustafson P, Alvegård T, Rydholm A. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific? APMIS 1995; 103:797-805. [PMID: 8546844 DOI: 10.1111/j.1699-0463.1995.tb01437.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Abnormal patterns of proliferation characterize the behavior of many tumors. Proliferating cell nuclear antigen (PCNA) and Ki-67 are two cell cycle antigens which are expressed in proliferative states. Our study examines the prognostic value of these cell-cycle antigens in soft tissue sarcoma (STS). Paraffin-embedded primary tumor tissues from 185 patients (1980-92) were stained with the anti-PCNA antibody PC-10; 182 of these were stained with the antibody MIB-1 for Ki-67. Using PCNA (< or = 50; > 50%) and Ki-67 (< or = 10; > 10%) indices, we examined and compared metastasis-free survival (MFS) in a mixed-histotype group, as well as after subdivision into MFH and non-MFH groups. Fifty-seven patients developed metastases. The median follow-up for survivors was 6 (2-13) years. In the mixed series, the 2-year MFS for a PCNA index < or = 50 was 76%, and for an index > 50 56%. Survival predicted by Ki-67 index was comparable. PCNA index (but not Ki-67) strongly correlated with the incidence of metastasis in MFH tumors and predicted 2-year MFS of 81 vs 48%. In contrast, Ki-67 index (but not PCNA) strongly correlated with metastasis in non-MFH tumors and predicted 2-year MFS survival of 90 vs 45%. No correlation existed between PCNA and Ki-67 indices in the mixed histotype, MFH or non-MFH groups. In combination, a high PCNA and Ki-67 index correlated with poor survival, a high PCNA and lower Ki-67 index (or vice versa) with an intermediate survival, and low PCNA and Ki-67 indices with the best survival. The pattern of PCNA and Ki-67 expression raises the possibility of histotype specificity.
Collapse
Affiliation(s)
- P F Choong
- Department of Orthopedics, Lund University Hospital, Sweden
| | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
The purpose of this article is to consolidate data collected from a variety of sources that have permitted calculations of the rates of growth of human neoplasms. These sources include Fischel State Cancer Hospital (Columbia, MO); Mallinckrodt Institute of Radiology, (St. Louis, MO); Roentgen Diagnostic Institute, Allmanna Sjukhuset (Malmo, Sweden); University of Louisville (Louisville, Kentucky); University of Heidelberg (Heidelberg, Germany); and St. Luke's Hospital (St. Louis, MO). Included in the data are laboratory measurements of cell replication rates. All gross measurements were made either on imaging studies or with a centimeter scale for surface or palpable neoplasms. Data have been reported for breast and pulmonary cancers and metastases of many types, melanomas, skeletal sarcomas, benign and malignant colonic neoplasms, and isolated cases of less frequent neoplasms. Related cytokinetic measurements by tritriated thymidine labelling, bromodeoxyuridine labelling, S-phase fraction from DNA flow cytometric analysis, and mitotic indices are discussed. The various mathematical formulae applicable to the analysis of the collected data and the determination of rates and patterns of growth are included. Also considered are the clinical implications of these data and the importance of ever better knowledge on the cytokinetics of human cancer. Prior studies on the evolution of insight into this field are cited and discussed. The authors conclude that a more accurate quantification of the growth rates of human cancer is essential for understanding the biological variance of human cancers seen clinically.
Collapse
Affiliation(s)
- J S Spratt
- Department of Surgery, James Graham Brown Cancer Center, University of Louisville School of Medicine, Kentucky 40202, USA
| | | | | |
Collapse
|
21
|
Resnick JM, Uhlman D, Niehans GA, Gapany M, Adams G, Knapp D, Jaszcz W. Cervical lymph node status and survival in laryngeal carcinoma: prognostic factors. Ann Otol Rhinol Laryngol 1995; 104:685-94. [PMID: 7661516 DOI: 10.1177/000348949510400903] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Elective cervical lymphadenectomy often is performed for laryngeal carcinoma to eliminate metastatic disease that escapes clinical and radiographic detection. We investigated characteristics of the primary tumor that might predict cervical lymph node status. We obtained archival tissue from 88 laryngectomies--65 with concurrent cervical lymphadenectomies. Of the 40 clinically negative necks that were dissected, 17% showed lymph node metastasis by pathologic examination. The primary tumors were examined immunohistochemically for expression of epidermal growth factor receptor (EGFR), p53, cathepsin D, proliferating cell nuclear antigen (PCNA), and Ki-67-specific antigen, and by flow cytometry for DNA ploidy-cell cycle analysis. Seventy-seven percent of the cases showed aberrant p53 staining, 99% expressed EGFR, 40% produced cathepsin D, 29% were aneuploid, and 54% had a moderate or high synthesis phase fraction (SPF). High grade, aneuploidy, and tumor vascular invasion independently predicted cervical node metastasis (p < .04 each). Supraglottic locale (p < .16) and a raggedly infiltrating invading margin (p < .13) were weakly associated with node positivity. Advanced clinical T status, the expression of EGFR, p53, and cathepsin D, the PCNA and Ki-67 indices, and SPF did not correlate with node metastasis. The presence of cervical node metastasis predicted poor disease-free (p < .005) and overall survival (p < .04). Advanced clinical T status correlated with brief overall survival (p < .02). Tumor site, histopathologic parameters, ploidy, SPF, PCNA and Ki-67 indices, and the expression of p53, EGFR, and cathepsin D did not affect survival. The presence of vascular invasion, high grade, and aneuploidy may help identify which patients would benefit from elective cervical lymphadenectomy. The correlation of cervical lymph node status and clinical T category with survival confirms the results of previous studies.
Collapse
Affiliation(s)
- J M Resnick
- Department of Laboratory Medicine, University of Minnesota Hospital and Clinic, Minneapolis, USA
| | | | | | | | | | | | | |
Collapse
|
22
|
Jensen V, Ladekarl M, Holm-Nielsen P, Melsen F, Soerensen FB. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J Pathol 1995; 176:343-52. [PMID: 7562249 DOI: 10.1002/path.1711760405] [Citation(s) in RCA: 83] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The prognostic value of oncogenic antigen 519 (OA-519) expression and tumour proliferative activity was evaluated in a retrospective series of 118 patients with low-risk breast cancer. Low risk was defined as negative axillary nodes, tumour diameter < or = 50 mm, and no histological evidence of invasion of skin or deep fascia (= T1N0M0 and T2N0M0). The median follow-up time was 104 months (range 5-143 months). Immunohistochemical analysis of OA-519 expression was performed on formalin-fixed, paraffin-embedded tissue. The proliferative activity was estimated using a Ki-67 equivalent monoclonal antibody (MIB-1), which is applicable on formalin-fixed, paraffin-embedded tissue after microwave pretreatment. OA-519 was expressed in about one-third of the tumours and the percentage of proliferating cells (the MIB-1 index) ranged between 1 and 72 per cent (median 17 per cent). Using multivariate Cox analysis, both the MIB-1 index and OA-519 expression were of independent prognostic value (2p < or = 0.01), and the combined immunohistological approach may therefore be useful in selecting patients with node-negative breast cancer who might benefit from adjuvant therapy.
Collapse
Affiliation(s)
- V Jensen
- Institute of Pathology, Aarhus Amtssygehus, Denmark
| | | | | | | | | |
Collapse
|
23
|
Paterlini P, Flejou JF, De Mitri MS, Pisi E, Franco D, Bréchot C. Structure and expression of the cyclin A gene in human primary liver cancer. Correlation with flow cytometric parameters. J Hepatol 1995; 23:47-52. [PMID: 8530809 DOI: 10.1016/0168-8278(95)80310-6] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
BACKGROUND/AIMS The cyclin A gene plays an important role in both the S and G2-M phases of the cell cycle, and has been identified at a site of hepatitis B virus DNA integration in a human liver cancer. We analyzed tumorous and non-tumorous samples from patients with primary liver cancer to determine whether a) the cyclin A gene is rearranged in liver tumors and b) the cyclin A transcript level correlates with the percentage of proliferating cells. METHODS Samples from 43 patients were analyzed by Southern blot. Cyclin A RNA accumulation was evaluated in 18 cases by slot blot and correlated with the percentage of cells in S plus G2-M phases defined by flow cytometry. RESULTS No rearrangement of the cyclin A gene was found in tumorous compared to non-tumorous tissue. A very strong positive correlation was found between the cyclin A RNA level and the cumulative percentage of cells in S plus G2-M phases (r = 0.99; p < 0.0001). CONCLUSIONS This in vivo study shows that the expression of cyclin A RNA correlates with the percentage of proliferating cells in primary liver cancer. Thus, cyclin A is a new potential liver tumor cell proliferation index.
Collapse
|
24
|
Abstract
Cancer is a disease of altered cellular genes. These altered genes, in turn, produce the malignant phenotype by inducing changes in proliferation and differentiation during the cell cycle. The changes can be assessed by techniques to measure proliferation and by histologic grading to distinguish levels of differentiation. Since proliferation factors and differentiation end points reflect the net effect of genetic damage and include, therefore, the accumulated changes in genes, they more aptly qualify as potential prognostic indicators than do individual oncogene alterations. By using mucoepidermoid carcinoma of the major salivary glands as the test model, I strongly suggest that a reproducible (three-tiered) grading system and measurements of proliferation (nuclear markers: proliferating cell nuclear antigen and, possibly, Ki-67; and proliferation fraction as determined by flow cytometry) can serve as cellular/molecular factors worthy of inclusion in existing clinical staging systems of salivary gland neoplasms.
Collapse
Affiliation(s)
- J G Batsakis
- Department of Pathology, University of Texas, M.D. Anderson Cancer Center, Houston 77030
| |
Collapse
|
25
|
Steck K, el-Naggar AK. Comparative flow cytometric analysis of Ki-67 and proliferating cell nuclear antigen (PCNA) in solid neoplasms. Cytometry 1994; 17:258-65. [PMID: 7851161 DOI: 10.1002/cyto.990170309] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The proliferation associated antigens, Ki-67 and proliferating-cell nuclear antigen (PCNA), have been widely used in studies assessing the growth fraction in human malignancies. It remains unclear, however, whether these markers yield similar assessments of proliferative activity in any given neoplasm. In this study, we compared Ki-67 and PCNA expression in 93 malignant solid neoplasms using bivariate flow cytometric analysis of these antigens and DNA content. The growth fractions measured by Ki-67 and PCNA were compared and correlated with acridine orange (AO) analysis and tumor grade. Our results indicate a significant difference between Ki-67 and PCNA values in neoplasms of low and intermediate grade (P = 0.002); Ki-67 values were significantly lower than those obtained by PCNA in this group. No statistical difference between Ki-67 and PCNA values was found in high grade neoplasms (P = 0.38). Analysis of different cell cycle compartments indicates that the observed difference in the positivity of these markers was due to their differential expression in the G0/1 segment of the cell cycle. We conclude that Ki-67 may better reflect the proliferative activity in solid neoplasms than does PCNA.
Collapse
Affiliation(s)
- K Steck
- Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston 77030
| | | |
Collapse
|
26
|
Wilson MS, Anderson E, Bell JC, Pearson JM, Haboubi NY, James RD, Schofield PF. An evaluation of five different methods for estimating proliferation in human colorectal adenocarcinomas. Surg Oncol 1994; 3:263-73. [PMID: 7889219 DOI: 10.1016/0960-7404(94)90028-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Five different methods of determining cell proliferation have been compared in samples taken from a group of 125 human colorectal tumours labelled in vivo with iododeoxy-uridine (IUdR). The labelling index (LI) was obtained immunocytochemically using monoclonal antibodies against proliferating cell nuclear antigen (PCNA), the Ki67 antigen and IUdR (IUdRimm). Incorporation of IUdR was also determined flow cytometrically (IUdRfcm) and PCNA expression was measured in both formalin- and methanol-fixed tissue (PCNAf and PCNAm respectively). There was significant variation in the results obtained both within and between the different assays. Paired analysis of the data showed that the correlation between the different methods of determining the LI was poor. However, the IUdRfcm LI was significantly correlated with both IUdRimm (r = 0.39; n = 78; P < 0.001 by Spearman's test) and Ki67 LIs (r = 0.32; n = 87; P < 0.001). The IUdRimm LI was also significantly related to the Ki67 LI (r = 0.44; n = 60; P < 0.001). The median IUdRfcm and IUdRimm LIs were significantly higher in the aneuploid vs. the diploid tumours (17.4% vs. 6.2% for IUdRfcm; 23.2% vs. 18.9 for the IUdRimm; P < 0.001 and P = 0.014 respectively by Mann-Whitney U-test) but none of the other proliferative indices showed this relationship. Finally, none of the LIs showed a significant association with the clinical characteristics of the tumours such as stage, grade, age, sex or fixity. The findings of this investigation highlight the need for carefully controlled studies when assessing the value of proliferation markers in solid human tumours.
Collapse
Affiliation(s)
- M S Wilson
- Department of Clinical Research, Christie Hospital NHS Trust, Manchester, UK
| | | | | | | | | | | | | |
Collapse
|
27
|
Mourad WA, Connelly JH, Sembera DL, Atkinson EN, Bruner JM. The correlation of two argyrophilic nucleolar organizer region counting methods with bromodeoxyuridine-labeling index: a study of metastatic tumors of the brain. Hum Pathol 1993; 24:206-10. [PMID: 8432516 DOI: 10.1016/0046-8177(93)90302-w] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Bromodeoxyuridine (BrdU) is a thymidine analog that is incorporated into cellular DNA in the synthetic phase. The BrdU-labeling index (BLI) thus reflects the S-phase fraction. The argyrophilic nucleolar organizer regions (AgNORs) are silver-stained granules that have been correlated with ploidy and/or S-phase fraction. Two AgNOR counting methods have been proposed to distinguish between ploidy and S-phase fraction: the mean AgNOR (mAgNOR) count (the mean number of AgNOR granules in 100 cells), which is believed to reflect ploidy, and the AgNOR proliferative index (pAgNOR) (the percentage of cells exhibiting five or more AgNOR granules per nucleus), which is believed to reflect S-phase fraction. To evaluate the latter hypothesis we studied 19 tumors metastatic to the brain in patients who had received preoperative low-dose BrdU injections. Formalin-fixed, paraffin-embedded sections of the resected tumors were stained using the indirect immunoperoxidase technique and a monoclonal antibody to BrdU. The BLI was determined by counting 1,000 tumor cells in each case; AgNOR silver staining was performed on sections of the same blocks studied for BLI. The correlation between pAgNOR counts and BLI was statistically significant (r = .649, P = .003). No statistically significant correlation could be obtained between mAgNOR counts and BLI (r = .421, P = .17). We conclude that the pAgNOR count can reliably reflect the proliferative activity of cells. The method can prove beneficial in situations in which cell kinetic analysis is needed and in which invasive procedures, such as BrdU injection, are not feasible or are contraindicated.
Collapse
Affiliation(s)
- W A Mourad
- Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston
| | | | | | | | | |
Collapse
|
28
|
van Weerden WM, Moerings EP, van Kreuningen A, de Jong FH, van Steenbrugge GJ, Schröder FH. Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models. Cell Prolif 1993; 26:67-75. [PMID: 8439590 DOI: 10.1111/j.1365-2184.1993.tb00007.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
The validity of the use of the monoclonal antibodies Ki-67 and anti-BrdUrd to evaluate proliferative activity of human prostate tumour models was studied. Growth of the transplantable PC-82 and PC-EW prostate tumours, as assessed by tumour volume measurements, was significantly correlated with the proliferative activity as reflected by BrdUrd incorporation into DNA (r = 0.64 and r = 0.78, respectively). The proliferative activity of PC-82 tumours detected by Ki-67 antigen expression paralleled the pattern observed with BrdUrd (r = 0.51) and a significant correlation (r = 0.60) between the results obtained with both markers was found. In growing PC-82 and PC-EW tumours only small variations in the Ki-67 and BrdUrd indices were observed. In contrast, Ki-67 expression in regressing PC-82 tumours varied considerably (2.7 +/- 2.2%). The BrdUrd index in regressing PC-82 tumours showed less variation (1.3 +/- 0.2%), but part of the BrdUrd-positive cells were found in the stromal (murine) part of the regressing tissue. It is concluded that the Ki-67 and BrdUrd proliferation markers are reliable parameters to monitor changes in growth of prostate tumour lines, but that in slow growing or regressing tumours Ki-67 and BrdUrd data should be interpreted with caution.
Collapse
Affiliation(s)
- W M van Weerden
- Department of Urology, Erasmus University, Rotterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
29
|
Affiliation(s)
- J M Coindre
- Department of Pathology, Fondation Bergonie, Bordeaux, France
| |
Collapse
|